{"owner": "ArrayExpress Uploader", "pop_total": 0, "id": 3751, "factors": [{"GSM568964": {"NUCLEAR RECEPTOR AGONIST TYPE": "control", "DONOR": 1, "AGENT": "vehicle"}}, {"GSM568965": {"NUCLEAR RECEPTOR AGONIST TYPE": "RAR and RXR agonist", "DONOR": 1, "AGENT": "9-cis retinoic acid"}}, {"GSM568966": {"NUCLEAR RECEPTOR AGONIST TYPE": "RXR agonist", "DONOR": 1, "AGENT": "LG268"}}, {"GSM568967": {"NUCLEAR RECEPTOR AGONIST TYPE": "PPARg agonist", "DONOR": 1, "AGENT": "rosiglitazone"}}, {"GSM568968": {"NUCLEAR RECEPTOR AGONIST TYPE": "PPARd agonist", "DONOR": 1, "AGENT": "GW1516"}}, {"GSM568969": {"NUCLEAR RECEPTOR AGONIST TYPE": "LXR agonist", "DONOR": 1, "AGENT": "GW3965"}}, {"GSM568970": {"NUCLEAR RECEPTOR AGONIST TYPE": "control", "DONOR": 2, "AGENT": "vehicle"}}, {"GSM56897": {"NUCLEAR RECEPTOR AGONIST TYPE": "RAR and RXR agonist", "DONOR": 2, "AGENT": "9-cis retinoic acid"}}, {"GSM568972": {"NUCLEAR RECEPTOR AGONIST TYPE": "RXR agonist", "DONOR": 2, "AGENT": "LG268"}}, {"GSM568973": {"NUCLEAR RECEPTOR AGONIST TYPE": "PPARg agonist", "DONOR": 2, "AGENT": "rosiglitazone"}}, {"GSM568974": {"NUCLEAR RECEPTOR AGONIST TYPE": "PPARd agonist", "DONOR": 2, "AGENT": "GW1516"}}, {"GSM568975": {"NUCLEAR RECEPTOR AGONIST TYPE": "LXR agonist", "DONOR": 2, "AGENT": "GW3965"}}, {"GSM568976": {"NUCLEAR RECEPTOR AGONIST TYPE": "control", "DONOR": 3, "AGENT": "vehicle"}}, {"GSM568977": {"NUCLEAR RECEPTOR AGONIST TYPE": "RAR and RXR agonist", "DONOR": 3, "AGENT": "9-cis retinoic acid"}}, {"GSM568978": {"NUCLEAR RECEPTOR AGONIST TYPE": "RXR agonist", "DONOR": 3, "AGENT": "LG268"}}, {"GSM568979": {"NUCLEAR RECEPTOR AGONIST TYPE": "PPARg agonist", "DONOR": 3, "AGENT": "rosiglitazone"}}, {"GSM568980": {"NUCLEAR RECEPTOR AGONIST TYPE": "PPARd agonist", "DONOR": 3, "AGENT": "GW1516"}}, {"GSM56898": {"NUCLEAR RECEPTOR AGONIST TYPE": "LXR agonist", "DONOR": 3, "AGENT": "GW3965"}}, {"GSM568982": {"NUCLEAR RECEPTOR AGONIST TYPE": "control", "DONOR": 4, "AGENT": "vehicle"}}, {"GSM568983": {"NUCLEAR RECEPTOR AGONIST TYPE": "RAR agonist", "DONOR": 4, "AGENT": "AM580"}}, {"GSM568984": {"NUCLEAR RECEPTOR AGONIST TYPE": "VDR agonist", "DONOR": 4, "AGENT": "1,25-dihydroxyvitamin D3"}}, {"GSM568985": {"NUCLEAR RECEPTOR AGONIST TYPE": "control", "DONOR": 5, "AGENT": "vehicle"}}, {"GSM568986": {"NUCLEAR RECEPTOR AGONIST TYPE": "RAR agonist", "DONOR": 5, "AGENT": "AM580"}}, {"GSM568987": {"NUCLEAR RECEPTOR AGONIST TYPE": "VDR agonist", "DONOR": 5, "AGENT": "1,25-dihydroxyvitamin D3"}}, {"GSM568988": {"NUCLEAR RECEPTOR AGONIST TYPE": "control", "DONOR": 6, "AGENT": "vehicle"}}, {"GSM568989": {"NUCLEAR RECEPTOR AGONIST TYPE": "RAR agonist", "DONOR": 6, "AGENT": "AM580"}}, {"GSM568990": {"NUCLEAR RECEPTOR AGONIST TYPE": "VDR agonist", "DONOR": 6, "AGENT": "1,25-dihydroxyvitamin D3"}}], "ownerprofile_id": "arrayexpress_sid", "platform": 4, "summary_wrapped": "CD14+ human monocytes differentiating into DCs in the presence of IL4 and GM-CSF were treated with agonists for RXR and its partners or...", "pubmed_id": 20861222, "geo_gse_id": "E-GEOD-23073", "owner_profile": "/profile/8773/arrayexpressuploader", "factor_count": 3, "sample_count": 27, "tags": ["dendritic", "monocyte"], "lastmodified": "Dec.12, 2014", "is_default": false, "geo_gds_id": "", "slug": "transcriptome-profiling-of-genes-regulated-by-rxr", "geo_id_plat": "E-GEOD-23073_A-AFFY-44", "name": "Transcriptome profiling of genes regulated by RXR and its partners in monocyte-derived dendritic cells", "created": "Sep.15, 2014", "summary": "CD14+ human monocytes differentiating into DCs in the presence of IL4 and GM-CSF were treated with agonists for RXR and its partners or vehicle 18 hours after plating (experiment with RXR and permissive partners, donor 1-3) or 14 hours after plating (experiment with nonpermissive partners, donor 4-6). Cells were harvested 12 hours thereafter. Experiments were performed in biological triplicates representing samples from three different donors.\u00a0 In this study all probable RXR-signaling pathways induced by agonists for RXR, LXRs, PPARs, RAR and VDR were identified in differentiating human monocyte-derived dendritic cells. In the experiments, differentiating dendritic cells were treated for 12 hours with one of the following compounds (ligands): vehicle (DMS:EtOH 1:1) LG268 (RXR agonist) 9-cis retinoic acid (9cisRA, agonist of RAR and RXR) GW3965 (LXRalpha/beta panagonist) rosiglitazone (RSG, PPARgamma agonist)\u00a0 GW1516 (PPARdelta agonist) AM580 (RARalpha agonist) 1,25-dihydroxyvitamin D3 (VDR agonist)", "source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-23073", "species": "human", "sample_source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-23073/samples/"}